Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.35 |
| ▸ | IKBKB | O14920 | 5/20 | 0.34 |
| ▸ | CHUK | O15111 | 5/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068960 | 0.75 | TRPV1 (0.40) | ADORA3ADORA1ADORA2AADORA2BGAA | |
| SCHEMBL5061315 | 0.74 | MAPT (0.44) | ADORA3ADORA1ADORA2AADORA2BGAA | |
| SCHEMBL5068900 | 0.74 | ADORA3 (0.57) | ADORA3ADORA1ADORA2AADORA2BGAA | |
| SCHEMBL16604726 | 0.74 | ADORA3 (0.34) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL5068853 | 0.72 | KDR (0.47) | ADORA3ADORA1ADORA2AADORA2BGAA | |
| SCHEMBL5064175 | 0.72 | KDR (0.47) | ADORA3ADORA1ADORA2AADORA2BGAA | |
| SCHEMBL5065463 | 0.71 | MAPT (0.45) | ADORA3ADORA1ADORA2AADORA2BGAA | |
| SCHEMBL24802393 | 0.71 | ADORA3 (0.33) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL16604682 | 0.68 | ADORA3 (0.33) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL1019277 | 0.68 | PKM (0.38) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-02-09 | — | — | US | disclosed |
| US-9518065-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | ADORA3 4217/4885ADORA1 3633/4885ADORA2A 3920/4885 |
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ADORA3 3456/4885ADORA1 3636/4885ADORA2A 3312/4885 |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ADORA3 3456/4885ADORA1 3636/4885ADORA2A 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.